CA_logo-blueCaring Ambassadors Hepatitis C Program

Monthly Medical Literature Review

December 2008



In The News


Schering-Plough to develop new oral hepatitis drug
“As part of its long-term commitment to hepatitis C therapy, Schering-Plough is developing SCH 900518 (518), a next-generation hepatitis C virus (HCV) protease inhibitor. A Phase IIa study with 518, known as the Next-1 study, is currently ongoing. The company said that 518 has been shown to be 10 times more potent in-vitro than other protease inhibitors currently in Phase III development and has the potential for once daily dosing. The protease inhibitor also has shown decreased emergence of resistance in vitro. Given its pharmacokinetic profile, the company anticipates that 518 may be active against some HCV strains that are resistant to other protease inhibitors.”


Inside-out cells offer target for antiviral drugs
“An experimental drug cured guinea pigs infected with a fatal hemorrhagic fever virus, raising hope for its use in a broad range of viral diseases including influenza, hepatitis C, HIV, Ebola and others, U.S. researchers said on Sunday. ‘This is a whole new strategy for making antiviral drugs,’ said Dr. Philip Thorpe, professor of pharmacology at the University of Texas Southwestern Medical Center at Dallas, whose research appears in the journal Nature Medicine.”
Read more…


Indiana addresses viral hepatitis

“State health officials say between 3.5 to 4 million Americans are living with viral hepatitis. In 2006, there were 4,723 reported cases of chronic and acute hepatitis C in Indiana, as well as 80 cases of hepatitis B, 33 cases of hepatitis A, and one case of hepatitis E. To address the problem in the state, the Indiana Viral Hepatitis Advisory Council has released ‘Indiana's Strategic Plan for the Prevention, Care, and Elimination of Viral Hepatitis.  ‘The purpose of the plan is to help our state move forward in raising awareness of viral hepatitis, to provide additional education and support for those living with the disease and their loved ones, and to ultimately reduce the burden of viral hepatitis in Indiana,’ said State Health Commissioner Judy Monroe, M.D.” Read more…

Study: Injection site saves lives, funds

“Canada's only supervised injection facility has extended lives of drug users and saved the healthcare system millions of dollars, a study indicates. When examining the cost-effectiveness of Insite, an injection facility in a Vancouver, British Columbia, neighborhood where about 5,000 injection drug users live, University of Western Ontario researchers said they found the facility saved about $14 million in healthcare costs and added about 920 life-years during a 10-year period.” Read more…


FDA nixes state appeal to ban multi-dose vials

The head of the U.S. Food and Drug Administration has rejected an appeal from New York State's health commissioner to ban the manufacture of multi-dose vials, saying they are an important option for hospitals.

In January, state Health Commissioner Dr. Richard Daines and New York City's health commissioner, Dr. Thomas Frieden, sent FDA Commissioner Dr. Andrew von Eschenbach a letter calling on the FDA to eliminate the manufacture and distribution of multi-dose vials.” Read more…



Clinical Trials, Cohort Studies, Pilot Studies

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.  Liu CH, Liu CJ, Lin CL, et al.  Clin Infect Dis. 2008 Nov 15;47(10):1260-9.


Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: A randomized clinical trial. Kawaoka T, Kawakami Y, Tsuji K, et al.  J Gastroenterol Hepatol. 2008 Nov 19. [Epub ahead of print]


The natural history of interferon-{alpha}2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection. Tran HA, Reeves GE, Jones TL. QJM. 2008 Nov 25. [Epub ahead of print]


Narcotic analgesics and progression of fibrosis in patients with chronic hepatitis C.

Vallejos C, Bordin-Wosk T, Pockros L, Feng A, Pockros P.  J Clin Gastroenterol. 2008 Nov 20. [Epub ahead of print]

The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age.  Selzner N, Girgrah N, Lilly L, et al.  Liver Transpl. 2008 Nov 24;14(12):1778-1786.

Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: Results of a prospective randomized study.  Lladó L, Fabregat J, Castellote J, et al.  Liver Transpl. 2008 Nov 24;14(12):1752-1760.

Hepatitis C virus therapy in liver transplant recipients: Response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.

Roche B, Sebagh M, Canfora ML, et al. Liver Transpl. 2008 Nov 24;14(12):1766-1777.


Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition.  Iacobellis A, Ippolito A, Andriulli A.  World J Gastroenterol. 2008 Nov 14;14(42):6467-72.


Presence of hepatitis C virus DNA sequences in the DNA of infected patients. Zemer R, Cohen YK, Naftaly T, Klein A.  Eur J Clin Invest. 2008 Nov;38(11):845-848.


Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. von Wagner M, Hofmann WP, Teuber G, et al.  Hepatology. 2008 Nov;48(5):1404-11.


Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis. Manrique A, Jiménez C, Ortega P, et al.  Transplant Proc. 2008 Nov;40(9):2962-4.

Orthotopic liver transplantation for hepatocellular carcinoma: a thirteen-year single-center experience. Castroagudín JF, Molina E, Bustamante M, et al.  Transplant Proc. 2008 Nov;40(9):2975-7.


IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Chuang JY, Yang SS, Lu YT, et al.  Dig Liver Dis. 2008 Nov 10. [Epub ahead of print]

Effects of hepatitis C virus infection on menopause status and symptoms. Cieloszyk K, Hartel D, Moskaleva G, Schoenbaum EE.  Menopause. 2008 Nov 7. [Epub ahead of print]

The relationship of hepatitis antibodies and elevated liver enzymes with impaired fasting glucose and undiagnosed diabetes

Mainous AG, Diaz VA, King DE, Everett CJ, Player MS.  . J Am Board Fam Med. 2008 Nov-Dec;21(6):497-503.


Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load.  Katamura Y, Suzuki F, Akuta N, et al.  Intern Med. 2008;47(21):1827-34.

Basic and Applied Science, Pre-Clinical Studies

Genetic markers of IgG influence the outcome of infection with hepatitis C virus. Pandey JP, Namboodiri AM, Luo Y, et al.  J Infect Dis. 2008 Nov 1;198(9):1334-1336.


Porphyria cutanea tarda, hepatitis C, uroporphyrinogen decarboxylase and mutations of HFE Gene. A case-control study. Cribier B, Chiaverini C, Dali-Youcef N, et al.  Dermatology. 2008 Nov 12. [Epub ahead of print]


Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire.  Wölfl M, Rutebemberwa A, Mosbruger T, et al.  J Immunol. 2008 Nov 1;181(9):6435-46.

Effect of interferon-alpha, ribavirin, pentoxifylline, and interleukin-18 antibody on hepatitis C sera-stimulated hepatic stellate cell proliferation. Khan F, Peltekian KM, Peterson TC.  J Interferon Cytokine Res. 2008 Nov;28(11):643-51.


Expression of apolipoprotein C-IV is regulated by Ku antigen/peroxisome proliferator-activated receptor gamma complex and correlates with liver steatosis.  Kim E, Li K, Lieu C, et al.  J Hepatol. 2008 Nov;49(5):787-98.


Skew in T cell receptor usage with polyclonal expansion in lesions of oral lichen planus without hepatitis C virus infection. Gotoh A, Hamada Y, Shiobara N, et al.  Clin Exp Immunol. 2008 Nov;154(2):192-201.

Hepatitis C virus core protein augments androgen receptor-mediated signaling. Kanda T, Steele R, Ray R, Ray RB.  J Virol. 2008 Nov;82(22):11066-72.


Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. Youn JW, Hu YW, Tricoche N,

et al.  J Virol. 2008 Nov;82(21):10896-905.


Kinetic analysis by real-time PCR of hepatitis C virus (HCV)-specific T cells in peripheral blood and liver after challenge with HCV. Ramalingam RK, Meyer-Olson D, Shoukry NH, Bowen DG, Walker CM, Kalams SA.  J Virol. 2008 Nov;82(21):10487-92.

Differential expression of the CXCR3 ligands in chronic hepatitis C, and their modulation by HCV in vitro. Helbig KJ, Ruszkiewicz A, Lanford RE, et al.  J Virol. 2008 Nov 5. [Epub ahead of print]


Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment. Taylor MW, Tsukahara T, McClintick JN, Edenberg HJ, Kwo P.  J Transl Med. 2008 Nov 5;6(1):66. [Epub ahead of print]


Subcellular localizations of the hepatitis C virus alternate reading frame proteins.  Ratinier M, Boulant S, Crussard S, McLauchlan J, Lavergne JP.  Virus Res. 2008 Nov 6. [Epub ahead of print]


Helical peptides derived from lactoferrin bind hepatitis C virus envelope protein e2. Beleid R, Douglas D, Kneteman N, Kaur K.  Chem Biol Drug Des. 2008 Nov;72(5):436-43.


Cellular vimentin content regulates the protein level of hepatitis C virus core protein and the hepatitis C virus production in cultured cells. Nitahara-Kasahara Y, Fukasawa M, Shinkai-Ouchi F, et al.  Virology. 2008 Nov 13. [Epub ahead of print]


Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury.  Zhu Z, Wilson AT, Mathahs MM, et al.  Hepatology. 2008 Nov;48(5):1430-9.


Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production.  Yang W, Hood BL, Chadwick SL, et al.  Hepatology. 2008 Nov;48(5):1396-403.


Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Zeremski M, Petrovic LM, Chiriboga L, et al.  Hepatology. 2008 Nov;48(5):1440-50.


Clinical relevance of the 2'-5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C.  Mihm U, Ackermann O, Welsch C, et al.  J Hepatol. 2008 Nov 11. [Epub ahead of print]


Role of molecular mimickry of hepatitis C-virus (HCV) protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia.  Zhang W, Nardi MA, Li Z, Borkowsky W, Karpatkin S.  Blood. 2008 Nov 20. [Epub ahead of print]

EWI-2wint - A host cell factor inhibiting hepatitis C virus entry. Schuster C, Baumert TF.  J Hepatol. 2008 Nov 5; [Epub ahead of print]

Interferon-alpha therapy does not modulate hepatic expression of classical type I interferon inducible genes. Meier V, Mihm S, Ramadori G, et al.  J Med Virol. 2008 Nov;80(11):1912-8.

HIV/HCV Coinfection

Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. Rodríguez-Nóvoa S, Morello J, González M, et al.  AIDS. 2008 Nov 30;22(18):2535-7.

Diagnosing acute hepatitis C in HIV-infected patients: Nucleic acid testing compared with antibody and antigen-antibody detecting methods.  Nastouli E, Thomson EC, Karayiannis P, Main J, McClure M, Muir D.  J Clin Virol. 2008 Nov 3. [Epub ahead of print]

Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.  Lopez-Cortes LF, Valera-Bestard B, Gutierrez-Valencia A, et al.  Clin Pharmacol Ther. 2008 Nov;84(5):573-80.

Complementary & Alternative Therapy

Treatment with silybin-vitamin E-phospholipid complex in patients with hepatitis C infection.  Falasca K, Ucciferri C, Mancino P, et al.  J Med Virol. 2008 Nov;80(11):1900-6.

Epidemiology, Diagnostics, and Miscellaneous Works


An evidence synthesis approach to estimating Hepatitis C Prevalence in England and Wales. De Angelis D, Sweeting M, Ades AE, Hickman M, Hope V, Ramsay M. Stat methods Med Res. 2008 Nov 26. [Epub ahead of print]


Estimating current injectors in Scotland and their drug-related death rate by sex, region and age-group via Bayesian capture-recapture methods. King R, Bird S, Hay G, Hutchinson S. Stat methods Med Res. 2008 Nov 26. [Epub ahead of print]

Modelling and calibration of the hepatitis C epidemic in Australia. Razali K, Amin J, Dore GJ, Law MG. World J Gastroenterol. 2008 Nov 21;14(43):6689-93.

Co-infection of hepatitis B and hepatitis C virus in human immunodeficiency virus-infected patients in New York City, United States. Kim JH, Psevdos G, Suh J, Sharp VL.World J Gastroenterol. 2008 Nov 21;14(43):6689-93.


Treating hepatitis C in the prison population is cost-saving. Tan JA, Joseph TA, Saab S.  Hepatology. 2008 Nov;48(5):1387-95.

Seroprevalence of select bloodborne pathogens and associated risk behaviors among injection drug users in the Paso del Norte region of the United States - Mexico border. Baumbach JP, Foster LN, Mueller M, et al. Harm Reduct J. 2008 Nov 16;5(1):33.

Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa. Cooper CL, Mills E, Wabwire BO, Ford N, Olupot-Olupot P.  Int J Infect Dis. 2008 Nov 10. [Epub ahead of print]


Single-cell-based image analysis of high-throughput cell array screens for quantification of viral infection. Matula P, Kumar A, Wörz I, et al.  Cytometry A. 2008 Nov 11. [Epub ahead of print]

Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus.  Butt AA, Tsevat J, Leonard AC, et al.  Int J Infect Dis. 2008 Nov 5. [Epub ahead of print]

Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. Helbling B, Overbeck K, Gonvers JJ, et al.  Gut. 2008 Nov;57(11):1597-603.

Whole blood as an alternative to plasma for detection of hepatitis C virus RNA.  Daniel HD, David J, Grant PR, Garson JA, Chandy GM, Abraham P. J Clin Microbiol. 2008 Nov;46(11):3791-4.

Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests.  Calès P, Boursier J, de Lédinghen V, et al.  Gastroenterol Clin Biol. 2008 Nov 17. [Epub ahead of print]